BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
OpenAI Rejects Apple Trade Secret Theft Claims 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Shein Shares Slide 9% in Hong Kong IPO Debut 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Add as a preferred source on Google
West Palm Beach, FL, March 19, 2018 -- For the first time, a groundbreaking new study is going to be conducted at a national treatment center. Ambrosia Treatment Center announced this month that they have been selected by Nova Southeastern University to participate in a cutting-edge drug study about the long-term effects of Gabapentin. Gabapentin, a drug for nerve pain, is administered by treatment centers across the nation to help clients suffering from the uncomfortable side effects of alcohol and cocaine withdrawal. If taken incorrectly, Gabapentin can be abused and hinder the recovery process. The study will be the first of its kind to see if the drug itself can be addictive.
|
|||
“Gabapentin is a controlled substance, and we need to learn more about this drug so it can continue to be used positively and correctly for the future of our client’s long-term success,” says Ambrosia Treatment Center founder Jerry Haffey Sr. “We have never opened our doors to a study of this magnitude, but we believe the findings will help us and treatment centers across the country better understand this drug and continue to help clients recover from addiction properly.”
Nova Southeastern University will select 100 clients from Ambrosia Treatment Center throughout the course of the year-long study to gain more insight on the effects of Gabapentin. Ambrosia Treatment Center has three locations in Palm Beach County, one in Beverly Hills and another in New Jersey. The study will be conducted at one of its three Palm Beach County locations.
About Ambrosia
Ambrosia Treatment Center has been raising industry standards for over 10 years and has treated over 10,000 clients at our locations nationwide. Our focus is on quality care, family involvement and advancing addiction medicine. To learn more, visit AmbrosiaTC.com.
Attachment:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/69f87b5a-6917-450a-8df2-a49150f55533
Parker Horveath Ambrosia Treatment Center 5615788600 [email protected]
